Teva Pharmaceutical Industries Limited (TEVA) Receives Outperform Rating from Royal Bank Of Canada

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “outperform” rating restated by analysts at Royal Bank Of Canada in a report issued on Monday, MarketBeat Ratings reports. They presently have a $37.00 price objective on the stock, down from their prior price objective of $38.00. Royal Bank Of Canada’s target price would indicate a potential upside of 15.99% from the stock’s current price.

TEVA has been the subject of a number of other research reports. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 target price for the company. in a research report on Monday, May 22nd. Jefferies Group LLC restated a “hold” rating and set a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. CIBC restated a “buy” rating and set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, April 7th. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, April 6th. Finally, Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, April 17th. Sixteen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $43.47.

Teva Pharmaceutical Industries Limited (TEVA) traded down 0.266% during mid-day trading on Monday, hitting $31.815. 7,351,449 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a 52 week low of $27.60 and a 52 week high of $55.79. The stock has a market capitalization of $32.32 billion, a PE ratio of 407.885 and a beta of 0.46. The company has a 50-day moving average of $30.42 and a 200-day moving average of $32.94.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. During the same quarter in the prior year, the business earned $1.20 earnings per share. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 17.0% on a year-over-year basis. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.78 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.wkrb13.com/markets/2303081/teva-pharmaceutical-industries-limited-nyseteva-price-target-cut-to-37-00-by-analysts-at-royal-bank-of-canada.html.

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock worth $154,602,000 after buying an additional 2,651,900 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock worth $46,065,000 after buying an additional 1,435,151 shares during the period. UBS Asset Management Americas Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 150.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 2,004,760 shares of the company’s stock worth $72,672,000 after buying an additional 1,205,253 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock worth $165,461,000 after buying an additional 801,106 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 142.2% in the first quarter. Ameriprise Financial Inc. now owns 1,288,571 shares of the company’s stock worth $41,349,000 after buying an additional 756,441 shares during the period. Institutional investors own 56.26% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2303081/teva-pharmaceutical-industries-limited-nyseteva-price-target-cut-to-37-00-by-analysts-at-royal-bank-of-canada.html

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.